2026 Global: Neuromodulation Devices And Implantable Infusion Pumps Market -Competitive Review (2032) report
Description
The 2026 Global: Neuromodulation Devices And Implantable Infusion Pumps Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Medtronic plc remains a dominant force in neuromodulation devices, offering implanted spinal cord stimulation, deep brain stimulation, and peripheral nerve stimulation systems alongside implantable infusion pumps for targeted drug delivery. The Dublin, Ireland headquartered company maintains a manufacturing and regulatory footprint that underpins expansion into chronic pain management, movement disorders, and epilepsy, with a focus on closed-loop options and battery longevity improvements. Abbott Laboratories, headquartered in Abbott Park, Illinois, United States, contributes a broad portfolio that includes neuromodulation platforms for persistent pain and movement disorders as well as intrathecal drug delivery systems. Its devices integrate wireless telemetry, clinician-optimized programming protocols, and safety features to enhance device longevity in hospital and outpatient settings. Boston Scientific Corporation, based in Marlborough, Massachusetts, United States, plays a critical role with spinal cord stimulation and peripheral nerve stimulation therapies, alongside implantable infusion pumps used in select intrathecal therapies under a global distribution network worldwide reach.
Nevro Corp., headquartered in Redwood City, California, United States, has propelled high-frequency spinal cord stimulation into mainstream pain management, emphasizing HF10 therapy and next-generation leads that reduce paresthesias while expanding coverage for back and leg pain. The company's global footprint supports large-scale clinical evidence generation and payer acceptance as it competes with conventional stimulation platforms. LivaNova PLC, based in London, United Kingdom, develops neuromodulation therapies including Vagus Nerve Stimulation for drug-resistant epilepsy and treatment-resistant depression, leveraging a legacy of Cyberonics integration to offer integrated care pathways across hospital and outpatient settings. Axonics, Inc., headquartered in Irvine, California, United States, markets a rechargeable sacral neuromodulation system and other implantable delivery devices that emphasize long-term battery life, MRI compatibility, and streamlined patient management. Together, these players extend the reach of implanted neuromodulation beyond traditional markets, while also contributing to targeted intrathecal drug delivery and closed-loop frameworks in dedicated specialties and emerging indications.
Neuropace, Inc., headquartered in Mountain View, California, United States, markets the RNS System for refractory epilepsy, representing a crucial brain neuromodulation modality that complements spinal and peripheral approaches in comprehensive neuromodulation portfolios. SetPoint Medical Corporation, based in Santa Monica, California, United States, pursues closed-loop neuromodulation for inflammatory and autoimmune conditions by integrating mood and autonomic targets with patient monitoring to optimize dosing and outcomes. Terumo Corporation, headquartered in Tokyo, Japan, contributes implantable infusion pump technologies and ancillary systems supporting complex intrathecal therapies and targeted drug delivery, alongside cardiovascular and other medical devices that diversify its modulation-related offerings. B. Braun Melsungen AG, headquartered in Melsungen, Germany, expands the implantable infusion pump segment with durable baclofen pumps and related intrathecal delivery solutions, aligning its engineering capabilities with global hospital networks and regulatory pathways. Together, these firms expand patient access and accelerate adoption of integrated neuromodulation and intrathecal delivery globally across healthcare systems.
Medtronic plc remains a dominant force in neuromodulation devices, offering implanted spinal cord stimulation, deep brain stimulation, and peripheral nerve stimulation systems alongside implantable infusion pumps for targeted drug delivery. The Dublin, Ireland headquartered company maintains a manufacturing and regulatory footprint that underpins expansion into chronic pain management, movement disorders, and epilepsy, with a focus on closed-loop options and battery longevity improvements. Abbott Laboratories, headquartered in Abbott Park, Illinois, United States, contributes a broad portfolio that includes neuromodulation platforms for persistent pain and movement disorders as well as intrathecal drug delivery systems. Its devices integrate wireless telemetry, clinician-optimized programming protocols, and safety features to enhance device longevity in hospital and outpatient settings. Boston Scientific Corporation, based in Marlborough, Massachusetts, United States, plays a critical role with spinal cord stimulation and peripheral nerve stimulation therapies, alongside implantable infusion pumps used in select intrathecal therapies under a global distribution network worldwide reach.
Nevro Corp., headquartered in Redwood City, California, United States, has propelled high-frequency spinal cord stimulation into mainstream pain management, emphasizing HF10 therapy and next-generation leads that reduce paresthesias while expanding coverage for back and leg pain. The company's global footprint supports large-scale clinical evidence generation and payer acceptance as it competes with conventional stimulation platforms. LivaNova PLC, based in London, United Kingdom, develops neuromodulation therapies including Vagus Nerve Stimulation for drug-resistant epilepsy and treatment-resistant depression, leveraging a legacy of Cyberonics integration to offer integrated care pathways across hospital and outpatient settings. Axonics, Inc., headquartered in Irvine, California, United States, markets a rechargeable sacral neuromodulation system and other implantable delivery devices that emphasize long-term battery life, MRI compatibility, and streamlined patient management. Together, these players extend the reach of implanted neuromodulation beyond traditional markets, while also contributing to targeted intrathecal drug delivery and closed-loop frameworks in dedicated specialties and emerging indications.
Neuropace, Inc., headquartered in Mountain View, California, United States, markets the RNS System for refractory epilepsy, representing a crucial brain neuromodulation modality that complements spinal and peripheral approaches in comprehensive neuromodulation portfolios. SetPoint Medical Corporation, based in Santa Monica, California, United States, pursues closed-loop neuromodulation for inflammatory and autoimmune conditions by integrating mood and autonomic targets with patient monitoring to optimize dosing and outcomes. Terumo Corporation, headquartered in Tokyo, Japan, contributes implantable infusion pump technologies and ancillary systems supporting complex intrathecal therapies and targeted drug delivery, alongside cardiovascular and other medical devices that diversify its modulation-related offerings. B. Braun Melsungen AG, headquartered in Melsungen, Germany, expands the implantable infusion pump segment with durable baclofen pumps and related intrathecal delivery solutions, aligning its engineering capabilities with global hospital networks and regulatory pathways. Together, these firms expand patient access and accelerate adoption of integrated neuromodulation and intrathecal delivery globally across healthcare systems.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
